Real-world evidence on Kovaltry (81-8973) in children with moderate or severe hemophilia A in Europe: a nested cohort analysis

Real-world evidence on Kovaltry (81-8973) in children with moderate or severe hemophilia A in Europe: a nested cohort analysis

Abstract Background Untreated hemophilia A patients may experience recurrent bleeding events leading to debilitating joint damages. While RCT and pharmacokinetic data support the value of Kovaltry [an unmodified full-length recombinant factor VIII (FVIII) product], real world evidence in children is...

Full description

Bibliographic Details
Main Authors: Jamie O’Hara, Ceri Hirst, Jose Francisco Cabre Marquez, Tom Burke
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Hemophilia A
Kovaltry
Real world evidence
Factor utilization
Clinical burden
Online Access:https://doi.org/10.1186/s13023-021-01676-w

Internet

https://doi.org/10.1186/s13023-021-01676-w

Similar Items